Shares of Quest Diagnostics Inc (NYSE:DGX) have earned a consensus recommendation of “Hold” from the twenty-one research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $114.37.

DGX has been the subject of a number of research analyst reports. Wells Fargo & Co raised shares of Quest Diagnostics from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $90.00 to $120.00 in a report on Tuesday, June 9th. Citigroup raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their price target for the company from $113.00 to $130.00 in a report on Monday, April 27th. UBS Group upped their price target on shares of Quest Diagnostics from $106.00 to $111.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Bank of America upped their price target on shares of Quest Diagnostics from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. Finally, TheStreet raised shares of Quest Diagnostics from a “c+” rating to a “b” rating in a report on Thursday, May 14th.

In related news, SVP Manner Carrie Eglinton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $111.02, for a total value of $555,100.00. Following the completion of the sale, the senior vice president now owns 24,890 shares of the company’s stock, valued at approximately $2,763,287.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Stephen H. Rusckowski sold 11,717 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $112.01, for a total value of $1,312,421.17. Following the completion of the sale, the chief executive officer now directly owns 249,464 shares of the company’s stock, valued at approximately $27,942,462.64. The disclosure for this sale can be found here. 1.49% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. State Street Corp boosted its position in Quest Diagnostics by 2.7% during the first quarter. State Street Corp now owns 6,818,798 shares of the medical research company’s stock worth $547,549,000 after purchasing an additional 179,263 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in Quest Diagnostics by 6.3% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 39,212 shares of the medical research company’s stock worth $3,149,000 after purchasing an additional 2,340 shares during the period. Optimal Asset Management Inc. boosted its position in Quest Diagnostics by 87.5% during the first quarter. Optimal Asset Management Inc. now owns 81,291 shares of the medical research company’s stock worth $6,528,000 after purchasing an additional 37,933 shares during the period. State of Tennessee Treasury Department boosted its position in Quest Diagnostics by 90.5% during the first quarter. State of Tennessee Treasury Department now owns 61,140 shares of the medical research company’s stock worth $4,910,000 after purchasing an additional 29,051 shares during the period. Finally, Highlander Capital Management LLC bought a new stake in shares of Quest Diagnostics in the first quarter valued at approximately $56,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

DGX stock traded up $0.20 during trading on Tuesday, hitting $110.42. The company had a trading volume of 1,478,300 shares, compared to its average volume of 1,697,796. The firm has a market capitalization of $14.81 billion, a price-to-earnings ratio of 19.01, a P/E/G ratio of 2.57 and a beta of 1.39. The business has a 50 day moving average of $112.81 and a 200 day moving average of $105.03. Quest Diagnostics has a fifty-two week low of $73.02 and a fifty-two week high of $125.00. The company has a current ratio of 1.38, a quick ratio of 1.27 and a debt-to-equity ratio of 0.71.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.06. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.76 billion. Quest Diagnostics had a net margin of 10.36% and a return on equity of 14.79%. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.40 earnings per share. As a group, equities analysts predict that Quest Diagnostics will post 5.62 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be issued a $0.56 dividend. The ex-dividend date is Tuesday, July 7th. This represents a $2.24 dividend on an annualized basis and a dividend yield of 2.03%. Quest Diagnostics’s dividend payout ratio is 34.15%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Story: Green Investing

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.